Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Endpoint Management and Adjudication Enhance Clinical Trials Platform

By BiotechDaily International staff writers
Posted on 17 Apr 2013
Endpoint adjudication management embedded within an electronic data capture platform optimizes the endpoint management and adjudication process, providing a collaborative and flexible workflow for all participants. Substantial cost effectiveness is achieved and cycle times reduced with a single, seamless system.

Merge Healthcare Incorporated (Chicago, IL, USA), a provider of clinical systems, recently added endpoint and adjudication management to its eClinical OS platform, providing end-to-end study support for trials of all sizes through a single platform.

“Merge eClinical has extensive experience working with the largest endpoint adjudication coordinating centers in the world. These relationships give us the unique experience to develop an endpoint adjudication module that is powerful, yet flexible enough to meet the complex requirements of all our clients. Merge’s latest enhancements to eClinical OS further our vision for delivering a unified solution for all data capture, processing, and return,” said Zaher El-Assi, general manager, eClinical solutions of Merge. “Through its single, easy-to-use interface, built-in study templates, libraries, and reports, and pay-as-you-go pricing, eClinical OS enables study sponsors and CROs to manage and run studies more efficiently than ever before.”

With Merge eClinical OS’ new Endpoint Adjudication Module, customers can: expedite cycle times with redaction tool and electronic compilation of source documents; auto-compile dossiers from source documents; reduce costs with fewer paper documents to track, ship, and review; Manage paired parallel, expert review and committee workflows; receive instant notifications that enable fast and efficient coordination; access reviewer assignments and dossiers from anywhere, at any time; and lastly, improve data quality through eCRFs and online edit checks.

“We began using eClinical OS towards the end of last year to manage and run our studies,” explained Thomas Engels, vice president of clinical affairs for CardioKinetix, Inc. (Menlo Park, CA, USA) “We’ve already seen enhanced efficiencies and improved productivity across the board, and are excited to begin using the new endpoint adjudication module to accelerate cycle times for adjudicating events.”

As a single, web-based system, Merge eClinical OS has the flexibility to support trials in any phase, and captures any type of data, from any source, over any modality. With a complete menu of clinical trial capabilities that can be mixed and matched, eClinical OS builds a solid foundation for each trial environment. Merge eClinical OS also has the scalability to grow if a trial increases in size, number, or complexity.

“We are obviously pleased by the positive customer response to eClinical OS,” stated Zaher El-Assi, general manager, eClinical Solutions of Merge. “Customer feedback has been integral to the product design, and I think it reflects a renewed focus on study efficiency. Merge eClinical OS places the control back in the users’ hands, resulting in shorter build times, faster implementation, and more cost effective trial design.”

Related Links:
Merge Healthcare



view channel
Image: representation of a protein (blue), which contains three zinc fingers in complex with DNA (orange). The coordinating amino acid residues and zinc ions (green) are highlighted (Photo courtesy of Wikimedia Commons).

Molecular Sensors Generated by Synthetic Biology Technique Using Intein-Based Protein Splicing

Biotech researchers have used intein-based protein splicing to generate synthetic protein components that are able to detect specific DNA sequences and subsequently trigger a desired intracellular response... Read more

Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more


view channel

Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company. Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI)... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.